Trial
NCT04676360
Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Jacob Soumerai, MD
Collaborators
GlaxoSmithKline
Condition
Relapsed Plasmablastic Lymphoma
Intervention
Belantamab Mafodotin
Why stopped
The study was closed given lack of efficacy and plans to publish this negative study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-13